Trial Profile
Cognitive Dysfunction in Patients With Major Depressive Disorder, Clinical Peculiarities, Biological Markers, and Treatment Efficacy
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Escitalopram (Primary) ; Vortioxetine (Primary)
- Indications Major depressive disorder
- Focus Therapeutic Use
- 15 Sep 2020 Results (n=125) presented at the 33rd Annual Congress of the European College of Neuropsychopharmacology
- 15 Sep 2020 Results (n=73) assessing vortioxetine treatment elevates serum BDNF levels in MDD patients along with the improvement of cognitive and emotional characteristics, presented at the 33rd Annual Congress of the European College of Neuropsychopharmacology
- 08 Jan 2019 Planned End Date changed from 1 Sep 2018 to 1 Apr 2019.